New drugs for BNCT: an experimental approach

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Development of novel boron-containing compounds for therapeutic applications.
• Exploration of boron compounds in cancer treatment strategies.

Purpose of the Study:

• To synthesize and evaluate new boron-containing drugs in preclinical murine tumor models.
• To assess the toxicity, biodistribution, and accumulation of these compounds in relevant tissues.

Main Methods:

• Administration of boron-containing ether lipid (B-Et-11-OMe) and boron-substituted ferrocenium derivatives to tumor-bearing mice.
• Boron quantification using alpha-particle sensitive films, ICP-AES, and ICP-MS.
• Evaluation of time-dependent biodistribution in tumors, organs, and tissues.

Main Results:

• B-Et-11-OMe was tested in mammary carcinoma (AT17) and osteosarcoma (OTS-64) models.
• Two boron-substituted ferrocenium derivatives exhibited high toxicity; a third showed potential for further investigation.
• Boron accumulation and biodistribution patterns were successfully determined using multiple analytical techniques.

Conclusions:

• New boron-containing compounds, including ether lipids and specific ferrocenium derivatives, demonstrate promise in preclinical cancer models.
• Biodistribution studies provide crucial data for understanding drug uptake and retention in tumors and organs.
• Further development and safety assessments are warranted for promising boron-drug candidates.